NNM Securities

COMPANY
more from company profile
HomeMarket Info Company Profile Smart Quotes

Smart Quotes

DIVI'S LABORATORIES LTD.

NSE : DIVISLABBSE : 532488ISIN CODE : INE361B01024Industry : Pharmaceuticals & DrugsHouse : Divis Labs
BSE3451.80-7.1 (-0.21 %)
PREV CLOSE ( ) 3458.90
OPEN PRICE ( ) 3420.10
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 31003
TODAY'S LOW / HIGH ( )3420.10 3501.00
52 WK LOW / HIGH ( )2730 3976.7
NSE3443.60-14.4 (-0.42 %)
PREV CLOSE( ) 3458.00
OPEN PRICE ( ) 3428.00
BID PRICE (QTY) 3443.60 (41613)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 1861153
TODAY'S LOW / HIGH( ) 3420.05 3503.75
52 WK LOW / HIGH ( )2730 3973.9
BSE
1D 1M 3M 1Y 3Y 5Y
STOCK SUMMARY
Incorporation Year : 12-10 1990
Management Info
Ramesh BV Nimmagadda - Chairman Murali K Divi - Managing Director
Registered Office

Address 1-72/23( P)/ Divis/303,Divi Towers, Cyber Hills,Gachibowli,
Hyderabad,
Telangana-500032

Phone 040 2378 6300 / 400

Email mail@divislabs.com

Website www.divislabs.com

Registrars Details
K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.)
Karvy Selenium Tower B, Plot 31-32,Gachibowli,Financial District,Nanakramguda,Hyderabad
 Listing : BSE, NSE, MCX
NEWS
23May Divi's Laboratories informs about secr
Pursuant to Regulation 24A of SEBI (Listing Obligations and Disclosure R..
22May Divi's Laboratories reports 64% fall i
Divi's Laboratories has reported results for fourth quarter (Q4) and yea..
13Apr Clarification To Query On 'Increase I
This is with reference to your email ref. no L/SURV/ONL/PV/KB/ 2023-2024..
11Apr Divi's Laboratories informs about cert
Divi's Laboratories has informed that it enclosed the certificate dated..
03Feb Divi's Laboratories reports 66% fall i
Divi's Laboratories has reported results for third quarter ended Decembe..
MORE
Financials
Rs. in Millions
QTR Mar 23 ANNUAL 23
Net Profit3187.918081.5
Gross Profit 4680.4 23541
Operating Profit 5548.526966.9
Net Sales 19081.776253
MORE
ROLLING FORWARD P/E (EOD)
EVENT CALENDAR
peer group
Astrazeneca Pharma I (BSE)
 3558.55 (6.90%)
M.Cap (Rs. in Cr)8896.38
Torrent Pharma (BSE)
 1844.35 (7.55%)
M.Cap (Rs. in Cr)62421.18
Shree Ganesh Remed. (BSE)
 339.45 (14.20%)
M.Cap (Rs. in Cr)436.10
AMI Organics (BSE)
 1217.15 (2.87%)
M.Cap (Rs. in Cr)4434.94
Hester Biosciences (BSE)
 1660.00 (1.64%)
M.Cap (Rs. in Cr)1412.14
MORE
Shareholding Pattern
PROMOTERS 51.94%
MUTUAL FUNDS/UTI 13.15%
NON-INSTITUTION 12.31%
FI/BANKS/INSURANCE 6.89%
GOVERNMENT 0%
FII 0%
MORE
Mf Holdings
MORE
ATTENTION INVESTORSKYCIPO
TERMS & CONDITIONS| PRIVACY POLICY| REFUND & CANCELLATION POLICY| DISCLAIMER| DISCLOSURE | CDSL e-Voting | SEBI| FMC| NSE| BSE| MCX | SCORES
Download Client Registration Documents (Rights & Obligations, Risk Disclosure Document, Do’s & Don’t’s) in Vernacular Language :
Assamese Bengali Gujrati Hindi Kanada
Kashmiri Konkani Malyalam Marathi Oriya
Punjabi Sindhi Tamil Telegu Urdu
REGISTRATION NOS.

NSE CM-INZ000234235|NSE F& O - INZ000234235, NSE CD-INZ000234235, BSE CM–INZ000234235 |BSE F & O - INZ000234235|BSE CD- INZ000234235 MCX-SX CM-INZ000234235|MCX-SX F & O - INZ000234235|MCX-SX CD-INZ000234235 NSDL - IN-DP-NSDL-319-2009ROC REG - 21-097912,CDSL : IN-DP-242-2016|SEBI-PMS: INP000007100

Filing compliant on SCORES – Easy & quick

  • Register on SCORES portal
  • Mandatory details for filing complaints on SCORES:
    • Name
    • PAN
    • Address
    • Mobile Number
    • E-mail ID
  • Benefits:
    • i.) Effective communication
    • ii.) Speedy redressal of the grievances
INVESTOR PROTECTION

Compliance officer : Apurva Mittal, Tel No: 022-40790035,022-40790024, Mobile No: 9152943075,9768009000, E-mail ID: compliance@nnmsecurities.com, cdsl@nnmsecurities.com

Investor grievance : support@nnmsecurities.com

Copyright © 2021 NNM Securities.com

Our Digital Marketing Partner: Public Media Solution

Designed , Developed & Content Powered by ●●● Accord Fintech Pvt. Ltd.